These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16639341)

  • 1. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.
    Shelton MJ; Ford SL; Borland J; Lou Y; Wire MB; Min SS; Xue ZG; Yuen G
    J Acquir Immune Defic Syndr; 2006 May; 42(1):61-7. PubMed ID: 16639341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
    Vourvahis M; Plotka A; Mendes da Costa L; Fang A; Heera J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6158-64. PubMed ID: 24080663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
    Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
    HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.
    Ford SL; Chen YC; Lou Y; Borland J; Min SS; Yuen GJ; Shelton MJ
    Antimicrob Agents Chemother; 2008 Feb; 52(2):534-8. PubMed ID: 18056271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
    Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
    Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.
    Cotton M; Cassim H; Pavía-Ruz N; Garges HP; Perger T; Ford SL; Wire MB; Givens N; Ross LL; Lou Y; Sievers J; Cheng K
    Pediatr Infect Dis J; 2014 Jan; 33(1):57-62. PubMed ID: 23811743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
    Gathe JC; Ive P; Wood R; Schürmann D; Bellos NC; DeJesus E; Gladysz A; Garris C; Yeo J
    AIDS; 2004 Jul; 18(11):1529-37. PubMed ID: 15238771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
    Shelton MJ; Wire MB; Lou Y; Adamkiewicz B; Min SS
    Antimicrob Agents Chemother; 2006 Mar; 50(3):928-34. PubMed ID: 16495253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
    Wire MB; Ballow CH; Borland J; Shelton MJ; Lou Y; Yuen G; Lin J; Lewis EW
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2982-4. PubMed ID: 17517848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
    Song I; Borland J; Chen S; Peppercorn A; Wajima T; Piscitelli SC
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6696-700. PubMed ID: 25155604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.
    Corbett AH; Patterson KB; Tien HC; Kalvass LA; Eron JJ; Ngo LT; Lim ML; Kashuba AD
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2756-61. PubMed ID: 16870769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
    Barbour AM; Gibiansky L; Wire MB
    J Clin Pharmacol; 2014 Feb; 54(2):206-14. PubMed ID: 25272370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
    Parks DA; Jennings HC; Taylor C; Pakes GE; Acosta EP
    HIV Clin Trials; 2009; 10(3):160-7. PubMed ID: 19632955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.
    Wire MB; Ballow C; Preston SL; Hendrix CW; Piliero PJ; Lou Y; Stein DS
    AIDS; 2004 Apr; 18(6):897-907. PubMed ID: 15060437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
    Cohen C; Dejesus E; Lamarca A; Young B; Yau L; Patel L; Vavro C; Wire MB; Wannamaker P; Shaefer M
    HIV Clin Trials; 2010; 11(5):239-47. PubMed ID: 21126954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
    Fortuny C; Duiculescu D; Cheng K; Garges HP; Cotton M; Tamarirt DP; Ford SL; Wire MB; Givens N; Ross LL; Lou Y; Perger T; Sievers J
    Pediatr Infect Dis J; 2014 Jan; 33(1):50-6. PubMed ID: 23811744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
    HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.